Prosztatarák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

14+ intézményből 14, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 202 125 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Törökország· EU contribution 398 612 EUR· until 2029. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.

5 of 32 running projects, newest first. Listed amounts together: 116,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Frissítve: 2025. nov. 6.

  “The Sponsor has achieved its objectives.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Genetic Testing for Men With Metastatic Prostate Cancer

  NCT03503097· University of Washington· Frissítve: 2025. okt. 1.

  “Study closed to accrual before meeting enrollment goal due to end of funding.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

  NCT04182516· Nerviano Medical Sciences· Frissítve: 2024. szept. 19.

  “The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer

  NCT00261456· Institute of Cancer Research, United Kingdom· Forrás

• Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations

  NCT02705846· Institute of Cancer Research, United Kingdom· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 153
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 464
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 61

• MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.

  PLoS Comput Biol, 2026. máj.

• Rapid Noninvasive Classification of Prostatic Disease Using Paper Spray Ionization Mass Spectrometry (PSI-MS)-Based Nontargeted Metabolomics.

  Anal Chem, 2026. ápr.

• Copper isotope fractionation and copper-to-zinc ratios reveal altered metal homeostasis in prostate cancer.

  Sci Rep, 2026. ápr.

• Plasma Proteomic Profiling Was Used to Discover a Biochemical Recurrence Prediction Model for Prostate Cancer.

  Mol Cell Proteomics, 2026. ápr.

• Autoencoder/RandomForest-TabPFN for cross-cancer metabolomics: prostate and breast cancer diagnosis using paper spray and ion mobility-mass spectrometry techniques.

  Gigascience, 2026. jan.

• Correlation between Selenium and Zinc Levels and Survival among Prostate Cancer Patients.

  Nutrients, 2024. febr.

• Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.

  EBioMedicine, 2021. jún.

• Preparation of catechin extracts and nanoemulsions from green tea leaf waste and their inhibition effect on prostate cancer cell PC-3.

  Int J Nanomedicine, 2016. máj.

• Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer.

  Int J Hyperthermia, 2015. márc.

• Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.

  Mol Cell Proteomics, 2013. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.